newsfilter
← Latest News
ACCESS Newswire·

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology